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major concern.  Indeed,  despite  promising  results,  it  is  still  unclear  which  patients  are  most  and
least likely  to  beneﬁt  from  this  procedure.
Aims.  —  To  identify  predictors  of  6-month  poor  clinical  outcomes  after  TAVI.
Abbreviations: AF, atrial ﬁbrillation; AR, aortic regurgitation; AS, aortic stenosis; CI, conﬁdence interval; EOA, effective oriﬁce area;
R, hazard ratio; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; OR, odds ratio; RV,
ight ventricular; SAVR, surgical aortic valve replacement; sPAP, systolic pulmonary artery pressure; STS, Society of Thoracic Surgeons;
AVI, transcatheter aortic valve implantation; TEE, transoesophageal echocardiography; TTE, transthoracic echocardiography; TR, tricuspid
egurgitation.
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Methods.  —  Patients  who  were  discharged  from  our  institution  with  a  transcatheter-implanted
aortic valve  were  followed  prospectively.  Our  population  was  divided  into  two  groups  (‘good
outcomes’  and  ‘poor  outcomes’)  according  to  occurrence  of  primary  endpoint  (composite  of
all-cause mortality,  all  stroke,  hospitalizations  for  valve-related  symptoms  or  worsening  heart
failure from  discharge  to  6  months  or  6-month  New  York  Heart  Association  functional  class  III  or
IV). Patient  characteristics  were  studied  to  ﬁnd  predictors  of  poor  outcomes.
Results.  —  We  included  163  patients  (mean  age,  79.9  ±  8.8  years;  90  men  [55%];  mean  logis-
tic EuroSCORE,  18.4  ±  11.4%).  The  primary  endpoint  occurred  in  49  patients  (mean  age,
83 ±  5  years;  31  men  [63%]).  By  multivariable  analysis,  atrial  ﬁbrillation  (odds  ratio  [OR]  3.94),
systolic pulmonary  artery  pressure  ≥  60  mmHg  (OR  7.56)  and  right  ventricular  dysfunction  (OR
3.55) were  independent  predictors  of  poor  outcomes,  whereas  baseline  aortic  regurgitation
≥ 2/4  (OR  0.07)  demonstrated  a  protective  effect.
Conclusion.  —  Atrial  ﬁbrillation,  severe  baseline  pulmonary  hypertension  and  right  ventricular
dysfunction  (i.e.  variables  suggesting  a  more  evolved  aortic  stenosis)  were  predictors  of  6-
month poor  outcomes.  Conversely,  baseline  aortic  regurgitation  ≥  2/4  showed  a  protective
effect, which  needs  to  be  conﬁrmed  in  future  studies.  Our  study  highlights  the  need  for  a
speciﬁc ‘TAVI  risk  score’,  which  could  lead  to  better  patient  selection.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  sélection  des  patients  pour  l’implantation  d’une  valve  aortique  transcathéter
(TAVI) demeure  un  challenge  clinique.  En  effet,  malgré  des  résultats  prometteurs,  il  reste
difﬁcile de  savoir  quels  patients  sont  les  moins  susceptibles  de  tirer  bénéﬁce  de  cette  procédure.
Objectif.  —  Notre  objectif  était  d’identiﬁer  des  facteurs  prédictifs  d’un  mauvais  résultat  6  mois
après TAVI.
Méthodes.  —  Nous  avons  prospectivement  suivi  les  patients  sortis  de  l’hôpital  avec  une  valve
aortique  implantée  par  voie  transcathéter.  Notre  population  a  été  divisée  en  2  groupes,
« bon  résultat  » et  « mauvais  résultat  »,  en  fonction  de  la  survenue  du  critère  primaire  qui
était un  critère  composite  des  décès  toutes  causes,  des  accidents  vasculaires  cérébraux,  des
hospitalisations  pour  insufﬁsance  cardiaque  ou  symptômes  en  rapport  avec  la  valve  entre
la sortie  de  l’hospitalisation  et  le  suivi  à  6  mois  ou  une  classe  fonctionnelle  New  York  Heart
Association  III  ou  IV  à  6  mois.  Les  caractéristiques  des  patients  ont  été  étudiées  aﬁn  de
déterminer  des  facteurs  prédictifs  de  mauvais  résultat.
Résultats.  — Cent  soixante-trois  patients  consécutifs  (âge  moyen  :  79,9  ±  8,8  ans  ;  90  hommes
[55 %])  ont  été  inclus.  L’EuroSCORE  logistique  moyen  était  de  18,4  ±  11,4  %.  Quarante-neuf
patients ont  présenté  le  critère  primaire.  En  analyse  multivariée,  la  ﬁbrillation  atriale  (OR  3,94),
une pression  artérielle  pulmonaire  systolique  ≥  60  mmHg  (OR  7,56),  une  dysfonction  ventric-
ulaire droite  (OR  3,55)  étaient  des  facteurs  prédictifs  indépendants  de  mauvais  résultat  alors
que l’insufﬁsance  aortique  préopératoire  ≥  2/4  (OR  0,07)  présentait  un  effet  protecteur.
Conclusion.  —  La  ﬁbrillation  atriale,  une  pression  artérielle  pulmonaire  systolique  ≥  60  mmHg
et une  dysfonction  ventriculaire  droite,  des  variables  évoquant  un  rétrécissement  aortique  plus
évolué, étaient  des  facteurs  prédictifs  de  mauvais  résultat  à  6  mois  après  TAVI.  À  l’inverse,  une
insufﬁsance  aortique  préopératoire  ≥  2/4  présentait  un  effet  protecteur  qui  doit  être  conﬁrmé
dans des  études  futures.  Notre  étude  souligne  la  nécessité  de  développer  un  score  de  risque
spéciﬁque  du  TAVI  qui  pourrait  améliorer  la  sélection  des  patients.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Aortic  stenosis  (AS)  is  the  most  common  valvular  disease,
with  an  increasing  incidence  in  the  elderly  population  [1].
Transcatheter  aortic  valve  implantation  (TAVI)  was  devel-
oped  as  an  alternative  to  surgical  aortic  valve  replacement
(SAVR)  in  patients  at  prohibitive  surgical  risk.  Several
registries  [2—4]  showed  functional  improvement  in  patients
with  severe  symptomatic  AS  treated  with  TAVI.  TAVI  demon-
strated  a  2-year  survival  advantage  over  medical  therapy
in  inoperable  patients  [5]  and  non-inferiority  against  SAVR
o
p
[n  high-risk  patients  [6]; it  is  now  the  standard  of  care  for
noperable  patients  and  a  valid  alternative  to  surgery  for
any  high-risk  patients  [7].
Despite  these  promising  results,  a  signiﬁcant  propor-
ion  of  patients  either  die  or  have  no  functional  beneﬁts
ithin  the  ﬁrst  months  after  TAVI  [2,5,6,8]. Numerous
redictors  of  mortality  have  been  identiﬁed,  such  as
ostprocedural  aortic  regurgitation  (AR)  [2,3,6,9],  chronic
bstructive  pulmonary  disease  [3], chronic  kidney  disease,
ulmonary  hypertension  and  postprocedural  complications
9].
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Moreover,  recently,  postprocedural  AR  and  severe  mitral
egurgitation  (MR)  were  identiﬁed  as  independent  predictors
f  poor  treatment  response  [8].  Nonetheless,  data  on  pre-
ictors  of  functional  outcomes  after  TAVI  are  scarce.  Yet,
iven  that  this  technique  is  generally  intended  for  elderly
atients,  symptomatic  improvement  is  as  critical  as  the
ncrease  in  life  expectancy.  A  risk  score  to  identify  those
atients  who  are  least  likely  to  beneﬁt  from  TAVI  should
urther  improve  the  selection  of  TAVI  candidates.
The  goal  of  this  prospective  study  was  to  identify  pre-
ictors  of  6-month  poor  outcomes  after  TAVI,  deﬁned  as  the
linical  components  of  ‘clinical  efﬁcacy’,  as  outlined  in  the
ecommendations  of  the  Valve  Academic  Research  Consor-
ium  [10].
ethods
atients
atients  with  severe  and  symptomatic  AS  (effective  oriﬁce
rea  [EOA]  ≤  1  cm2)  who  underwent  TAVI  at  our  institution
ere  prospectively  enrolled.  Exclusion  criteria  were  death
uring  the  procedure  or  subsequent  hospitalization,  conver-
ion  to  surgery  or  unsuccessful  implantation  (deﬁned  as
mpossibility  to  deliver  and  deploy  a  valve  into  the  proper
ocation  for  anatomical  reasons).  Before  TAVI,  these  patients
nderwent  an  evaluation,  which  included  a  physical  exam-
nation,  blood  tests,  transthoracic  and  transoesophageal
chocardiography  (TTE  and  TEE,  respectively)  and  com-
uterized  tomography.  Indications,  contraindications  and
natomical  requirements  for  TAVI  have  been  described  pre-
iously  [7].  SAVR  risk  of  mortality  was  estimated  using  the
ogistic  EuroSCORE  [11]  and  the  Society  of  Thoracic  Surgeons
STS)  risk  score  [12].  Finally,  TAVI  indication  was  retained
y  a  multidisciplinary  ‘Heart  Team’  based  on  the  evalu-
tion  cited  above.  Patients  were  followed  on-site  before
ischarge,  1  month  after  implantation  and  either  on-site  or
y  their  cardiologist  6  months  after  TAVI.  Follow-up  informa-
ion  was  also  obtained  by  telephone  contact  with  deceased
atients’  physicians.  Patients  gave  written  informed  consent
efore  participation.  The  study  was  approved  by  the  local
thics  committee.
ndpoints
he  primary  endpoint  was  the  clinical  components  of  ‘clin-
cal  efﬁcacy’  [10]  (i.e.  a  composite  of  all-cause  mortality,
ll  stroke  [disabling  and  non-disabling],  hospitalizations  for
alve-related  symptoms  or  worsening  heart  failure  from  dis-
harge  to  6  months  or  a  6-month  New  York  Heart  Association
NYHA]  class  III  or  IV).  Secondary  endpoints  were  clinical
fﬁcacy,  as  deﬁned  in  the  recommendations  of  the  Valve
cademic  Research  Consortium  [10]  (clinical  components
r  valve-related  dysfunction,  i.e.  mean  aortic  valve  gradi-
nt  ≥  20  mmHg,  EOA  ≤  0.9—1.1  cm2 and/or  Doppler  velocity
ndex  <  0.35  m/s  and/or  moderate  or  severe  prosthetic  valve
egurgitation),  and  6-month  all-cause  mortality.  The  cohort
as  subsequently  divided  into  two  groups:  ‘good  outcomes’
nd  ‘poor  outcomes’,  according  to  the  occurrence  of  the
rimary  endpoint.
Atrial  ﬁbrillation  (AF)  was  deﬁned  as  any  history  of  AF
egardless  of  type  of  arrhythmia  or  presence  of  AF  on  at
w
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a
(V.  Auffret  et  al.
east  one  electrocardiogram  during  hospitalization  for  the
reoperative  assessment  or  the  day  before  TAVI.  Coronary
rtery  disease  was  deﬁned  as  presence  of  lesions  with  ≥  50%
iameter  stenosis  on  pre-TAVI  angiography  and/or  previ-
us  treatment  with  percutaneous  coronary  intervention  or
oronary  artery  bypass  grafting.  Complications  were  deﬁned
ccording  to  the  recommendations  of  the  Valve  Academic
esearch  Consortium  [10].
tudy devices and procedures
he  two  CE-approved  prostheses  and  implantation  tech-
iques  have  been  described  previously  [2,4].  The  procedure
as  performed  in  a  catheterization  laboratory  in  a  sterile
nvironment  by  at  least  two  interventional  cardiologists,
 cardiac  surgeon  and  an  anaesthesiologist.  The  choice  of
hether  to  use  local  or  general  anaesthesia  was  left  at  the
iscretion  of  the  anaesthesiologist  in  charge  of  the  patient.
he  type  of  anaesthesia  used  was  not  recorded  routinely  in
ur  database,  but  was  known  for  81%  (n  =  132)  of  patients,
6%  of  whom  (n  =  87)  underwent  local  anaesthesia.  TEE  was
sed  for  transapical  cases,  to  accurately  deﬁne  the  apical
urgical  access  site.  Fluoroscopy  was  used  for  valve  posi-
ioning  in  all  cases,  with  the  help  of  TEE  guidance  only  in
ransapical  cases.
chocardiography
TE  was  performed  according  to  the  American  Society
f  Echocardiography  guidelines  [13]  by  an  experienced
chocardiographer  using  a  digital  ultrasound  scanner
Vivid7,  GE  Healthcare,  Little  Chalfont,  UK;  or  iE33,  Philips
ealthcare,  Andover,  MA,  USA).
In  apical  ﬁve-chamber  view,  peak  and  mean  pressure  gra-
ients  across  the  aortic  valve  were  calculated  using  the
ernoulli  equation.  EOA  was  calculated  using  the  continuity
quation.
A  multiparametric  approach  with  both  semiquantitative
nd  quantitative  variables  was  used  to  grade  valvular  regur-
itation  on  a  scale  from  0  to  4,  with  higher  grades  indicating
reater  severity  (0,  no;  1,  mild;  2,  moderate;  3/4,  severe).
aseline  and  postprocedural  AR  were  graded  in  accordance
ith  the  European  Society  of  Cardiology  guidelines  for  native
alves  [14].  However,  given  the  frequent  eccentric  and
rregular  jet  of  postprocedural  AR,  we  also  gave  a  heavy
eighting  to  the  circumferential  extent  of  prosthetic  AR  in
arasternal  short-axis  view,  to  provide  an  integrated  assess-
ent  of  postprocedural  AR  [10]. Thresholds  were  as  follows:
one,  no  regurgitant  colour  ﬂow;  mild  extent,  <  10%;  moder-
te  extent,  10—29%;  severe  extent,  ≥  30%.  Before  TAVI,  we
sed  TEE  to  measure  the  annulus  diameter  accurately  and
ometimes  to  grade  AR  or  MR  when  TTE  was  not  conclusive.
Pulmonary  hypertension  was  deﬁned  as  systolic  pul-
onary  artery  pressure  (sPAP)  ≥  40  mmHg  at  rest,  estimated
sing  tricuspid  regurgitation  (TR)  velocity  [15].  Right  atrial
ressure  was  assessed  using  inferior  vena  cava  diameter  (in
ts  long  axis)  and  inspiratory  collapse  in  the  subcostal  view
15]: a  diameter  ≤  21  mm  and  a  collapse  >  50%  with  a  sniff
ere  used  as  cut-offs  for  normal  right  atrial  pressure  (i.e.
 mmHg,  range  0—5  mmHg),  whereas  a  diameter  >  21  mm
nd  a collapse  <  50%  deﬁned  high  right  atrial  pressure
15  mmHg,  range  10—20  mmHg).  In  indeterminate  cases,
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in  which  the  inferior  vena  cava  diameter  and  collapse
did  not  ﬁt  these  deﬁnitions,  an  intermediate  value  of
8  mmHg  (range  5—10  mmHg)  was  used.  Right  ventricular
(RV)  function  was  assessed  in  apical  four-chamber  view
using  tricuspid  annular  plane  systolic  excursion  measured
by  M-mode,  with  a  reference  value  for  impaired  RV  systolic
function  of  <  16  mm  and  an  RV  peak  systolic  velocity  of
the  tricuspid  annulus  measured  by  tissue  Doppler,  with
a  value  of  ≥  10  cm/s  deﬁning  normal  RV  function  [15].
Left  ventricular  ejection  fraction  (LVEF)  was  measured  by
Simpson’s  method  from  the  four-  and  two-chamber  views
[13].  Left  atrial  end-systolic  area  was  measured  from  the
four-chamber  apical  view.  LV  end-diastolic  and  end-systolic
diameters  and  end-diastolic  septal  thickness  were  measured
by  M-mode  from  parasternal  views.
TTE  was  performed  the  day  before  TAVI,  before  discharge
and  1  month  and  6  months  after  TAVI.
Blood tests
Venous  blood  samples  were  obtained  on  the  day  before
TAVI  to  determine  concentrations  of  N-terminal  pro  B-type
natriuretic  peptide  and  serum  creatinine.  The  estimated
glomerular  ﬁltration  rate  was  calculated  using  the  abbre-
viated  Modiﬁcation  of  Diet  in  Renal  Disease  Study  equation.
Kidney  disease  was  deﬁned  as  moderate  when  the  glomeru-
lar  ﬁltration  rate  was  between  30  and  59  mL/min/1.73  m2
and  as  severe  when  <  30  mL/min/1.73  m2.
Statistical analysis
Numeric  values  are  expressed  as  mean  ±  standard  devia-
tion.  Normality  was  tested  using  the  Kolmogorov-Smirnov
test.  Continuous  variables  were  compared  using  the
unpaired  t-test  or  the  Mann-Whitney  U  test,  as  appropriate.
Chi-square  analysis  or  Fisher’s  exact  test  was  used  to
compare  categorical  variables.  Patient  characteristics  were
evaluated  for  poor  outcomes.  All  baseline  variables  with
a  P  value  ≤  0.2  in  univariate  analysis  were  entered  into
an  ascending  stepwise  multivariable  logistic  regression
analysis  to  identify  independent  predictors  of  poor  out-
comes  and  into  an  ascending  stepwise  Cox  multivariable
analysis  to  identify  predictors  of  all-cause  mortality.  The
likelihood  ratio  statistic  was  used  at  each  step  to  deﬁne
which  variable  should  be  included  in  or  excluded  from
the  model.  Variables  with  a  P  value  <  0.05  were  added
to  or  remained  in  the  model,  whereas  variables  with  a  P
value  ≥  0.1  were  removed.  Results  are  presented  as  odds
ratios  (ORs)  and  hazard  ratios  (HRs).  A  P  value  ≤  0.05  was
considered  signiﬁcant.  All  probability  values  reported  are
two-sided.  Statistical  analysis  was  performed  with  the  use
of  SPSS  21.0  software  (SPSS,  Inc.,  Chicago,  IL,  USA).
Results
Patients
From  January  2009  to  June  2012,  514  consecutive  patients
with  severe  and  symptomatic  AS  were  referred  to  our  insti-
tution  for  pre-TAVI  evaluation.  After  meetings  of  the  Heart
Team,  TAVI  indication  was  conﬁrmed  in  180  patients  who
underwent  the  procedure  from  February  2009  to  July  2012.
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 total  of  17  patients  died  during  the  procedure  (n  =  3)  or
he  initial  hospitalization  (n  =  6),  were  converted  to  surgery
n  =  4:  two  annulus  ruptures;  two  embolizations  of  the
rosthesis  in  the  left  ventricle)  or  had  unsuccessful  implan-
ation  (n  =  6:  ﬁve  non-fatal  vascular  access  complications,
ne  insufﬁcient  distance  between  valvular  plane  and  a
ircumﬂex  artery  with  an  anomalous  origin  from  the  right
inus  of  Valsalva)  and  thus  were  excluded.  Our  study  cohort
ncluded  163  surviving  patients  (Fig.  1).  No  patient  was  lost
o  follow-up.
The  mean  age  of  the  study  patients  was  79.9  ±  8.8  years,
0  patients  (55.2%)  were  men,  the  mean  logistic  EuroSCORE
as  18.4  ±  11.4%,  the  mean  STS  risk  score  was  5.8  ±  3.1%,
18  patients  (72.4%)  were  NYHA  functional  class  III  or  IV,  86
atients  (52.8%)  had  a  history  of  acute  heart  failure  and  71
atients  (44%)  had  AF.  The  baseline  characteristics  of  the
tudy  population  are  summarized  in  Table  1.
rocedural outcomes
he  aortic  valve  prosthesis  was  inserted  using  the  retrograde
emoral  artery  approach  (n  =  132),  the  subclavian  artery
pproach  (n  =  10),  the  transapical  approach  (n  =  12)  or  the
ransaortic  approach  (n  =  9).  The  implanted  prosthesis  was
n  Edwards  SAPIEN  (n  =  8),  an  Edwards  SAPIEN  XT  (n  =  91)
r  a  Medtronic  CoreValve  (n  =  64).  Valve  size  was  23  mm
n  =  32),  26  mm  (n  =  63)  or  29  mm  (n  =  4)  for  the  Edwards
evices  and  26  mm  (n  =  20),  29  mm  (n  =  36)  or  31  mm  (n  =  8)
or  the  Medtronic  CoreValve.
The  mean  total  procedural  time  was  96  ±  31  minutes
nd  the  mean  contrast  agent  volume  was  238.8  ±  92.7  mL.
alve  embolization  in  the  aorta  was  observed  in  two  cases
nd  was  managed  with  implantation  of  a  second  prosthe-
is.  Acute  kidney  injury  stage  2  or  3  arose  in  10  patients
6.1%),  including  one  who  required  temporary  dialysis.
ixteen  patients  (9.8%,  15  CoreValve)  received  a  new  per-
anent  pacemaker.  Procedural  outcomes  are  summarized  in
able  2.
ortality and poor outcomes
leven  patients  died  (eight  of  cardiovascular  causes)
etween  discharge  from  hospital  and  6-month  follow-up.
hus,  6-month  all-cause  mortality  rate  was  6.7%  for  the
tudy  population  and  11.1%  for  the  180  patients  who  under-
ent  the  procedure.
Twenty-three  of  152  remaining  study  patients  were  NYHA
unctional  class  III  or  IV  at  6-month  follow-up.  Hospitaliza-
ion  for  heart  failure  occurred  in  32  patients;  no  stroke
ccurred  after  the  initial  hospitalization.  Eventually,  49
atients  (30.1%)  met  the  criteria  for  the  ‘poor  outcomes’
roup.  The  114  remaining  patients  (69.9%)  formed  the  ‘good
utcomes’  group.
All  clinical  characteristics  with  signiﬁcant  differences
etween  groups  are  presented  in  Table  1.  A  total  of  69
42.3%)  patients  met  the  criteria  for  clinical  efﬁcacy.
chocardiographical ﬁndingsost  patients  had  preserved  LVEF  (mean  LVEF,  50.7  ±  14.8%)
nd  only  25  patients  (16%)  had  an  LVEF  ≤  30%.  Thirty-six
atients  (22.1%)  had  moderate  or  severe  (≥  2/4)  AR  at
aseline.  MR  ≥  2/4  was  present  in  65  patients  (39.9%;
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Figure 1. Flowchart. *: one patient died during surgical aortic valve replacement after aortic annulus rupture during transcatheter
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sortic valve implantation. †:  one patient died during the initial hos
mplantation.
oderate,  n  =  57;  severe,  n  =  8).  RV  dysfunction  was
bserved  in  31  patients  (19.0%)  and  38  patients  (23.3%)
ad  TR  ≥  2/4  (moderate,  n  =  26;  severe,  n  =  12).  Pulmonary
ypertension  was  diagnosed  in  65.0%  of  patients;  it  was
oderate  (40  ≤  sPAP  ≤  59  mmHg)  in  70  patients  (42.9%)  and
evere  (sPAP  ≥  60  mmHg)  in  36  patients  (22.1%).  Overall,
PAP  improved  in  61  of  the  106  patients  (57.5%)  with
aseline  pulmonary  hypertension.
AR  was  common  after  TAVI,  as  115  patients  (70.6%)  pre-
ented  a  leak,  but  AR  ≥  2/4  was  present  in  only  30  patients
18.6%).  Regarding  patients  with  postprocedural  AR  ≥  2/4,
/16  patients  (56.2%)  in  the  good  outcomes  group  com-
ared  with  only  1/14  patients  (7.1%)  in  the  poor  outcomes
roup  had  baseline  AR  ≥  2/4.  Echocardiographical  ﬁndings
re  summarized  in  Table  3.redictors of  6-month poor outcomes
ll  variables  with  a  P  value  ≤  0.2  in  univariate  analysis  for
oor  outcomes  are  listed  in  Table  4.  These  variables  were
A
P
(zation after conversion to surgery. TAVI: transcatheter aortic valve
ntered  into  a  stepwise  multivariable  logistic  regression
nalysis  that  identiﬁed  AF  (OR  3.94,  95%  conﬁdence  inter-
al  [CI]  1.67—9.29;  P  =  0.002),  RV  dysfunction  (OR  3.55,
5%  CI  1.21—10.39;  P  =  0.02)  and  severe  baseline  pulmonary
ypertension  (OR  7.56,  95%  CI  2.58—22.17;  P  <  0.001)  as
ndependent  predictors  of  6-month  poor  outcomes,  whereas
aseline  AR  ≥  2/4  (OR  0.07,  95%  CI  0.02—0.32;  P  =  0.001)
emonstrated  a  protective  effect  (Table  4).
redictors of secondary endpoints
ll  variables  with  a  P  value  ≤  0.2  in  univariate  analysis  for
econdary  endpoints  are  listed  in  Tables  5  and  6.
Independent  predictors  of  clinical  efﬁcacy  (Table  5)
ere  AF  (OR  4.09,  95%  CI  1.99—8.39;  P  <  0.001)  and
PAP  ≥  60  mmHg  (OR  3.84,  95%  CI  1.52—9.72;  P  =  0.004).
gain,  baseline  AR  ≥  2/4  (OR  0.30,  95%  CI  0.11—0.79;
 =  0.015)  showed  a protective  effect.
In  a  stepwise  Cox  multivariable  model,  STS  risk  score
hazard  ratio  [HR]  1.32,  95%  CI  1.11—1.57;  P  =  0.002),  prior
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Table  1  Characteristics  of  the  study  patients  at  baseline.
Characteristics  All  patients  Good  outcomes  Poor  outcomes  P
(n  =  163)  (n  =  114)  (n  =  49)
Age  (years)  79.9  ±  8.8  78.6  ±  9.7  82.8  ±  5.0  0.01
Men  90  (55.2)  59  (51.8)  31  (63.3)  0.24
Body  surface  area  (m2)  1.78  ±  0.2  1.77  ±  0.2  1.81  ±  0.3  0.63
Logistic  EuroSCORE  (%)  18.4  ±  11.4  17.4  ±  10.6  20.7  ±  12.7  0.12
STS  risk  score  (%) 5.8  ±  3.1 5.4  ±  3.0  6.0  ±  3.0  0.002
NYHA  class  III  or  IV 118 (72.4) 76  (66.7) 42  (85.7)  0.02
Angina  pectoris 32  (19.6) 25  (21.9) 7  (14.3) 0.36
Syncope  21  (12.9) 19  (16.7) 2  (4.1) 0.04
Previous  acute  heart  failure  86  (52.8)  57  (50.0)  29  (59.2)  0.36
Clinical  history
CAD  85  (52.1)  64  (56.1)  21  (42.9)  0.17
Previous  PCI  24  (14.7)  18  (15.8)  6  (12.2)  0.73
Previous  BAV 29  (17.8) 16  (14.0) 13  (26.5) 0.09
Previous  CABG 28  (17.2) 21  (18.4) 7  (14.3) 0.68
Previous  SAVR  3  (1.8)  2  (1.8)  1  (2.0)  1.0
Cerebrovascular  disease  24  (14.7)  17  (14.9)  7  (14.3)  1.0
PVD  32  (19.6)  26  (22.8)  6  (12.4)  0.18
Porcelain  aorta  11  (6.7)  8  (7.0)  3  (6.1)  1.0
AF  71  (43.5)  37  (32.5)  34  (69.4)  <  0.0001
Chest  wall  irradiation  21  (12.9)  19  (16.7)  2  (4.1)  0.04
Hypertension  108  (66.3)  69  (60.5)  39  (79.6)  0.03
Diabetes  mellitus  27  (16.6)  20  (17.5)  7  (14.3)  0.78
COPD  63  (38.9)  41  (36.3)  22  (44.9)  0.39
Chronic  kidney  disease  0.47
Moderate  66  (40.5)  43  (37.7)  23  (46.9)
Severe  6  (3.7)  5  (4.4)  1  (2.0)
NT-proBNP  (pg/mL)  4281.3  ±  4378.4  4329.6  ±  4724.1  4172.1  ±  3518.2  0.36
Data are mean ± standard deviation or number (%). AF: atrial ﬁbrillation; BAV: balloon aortic valvuloplasty; CABG: coronary artery
bypass graft; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; NT-proBNP: N-terminal prohormone of brain
natriuretic peptide; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; PVD: peripheral vascular disease;
SAVR: surgical aortic valve replacement; STS: Society of Thoracic Surgeons.
p
i
l
o
A
A
m
m
e
b
t
p
u
L
t
evalvuloplasty  (HR  4.31,  95%  CI  1.26—14.70;  P  =  0.02),  aor-
tic  annulus  diameter  (HR  1.50,  95%  CI  1.12—2.00;  P  =  0.007)
and  left  atrial  area  (HR  1.12,  95%  CI  1.01—1.25;  P  =  0.04)
were  independent  predictors  of  6-month  all-cause  mortality
(Table  6).
Discussion
TAVI  is  now  the  standard  of  care  for  ‘inoperable’  patients
and  a  valid  alternative  to  surgery  for  many  high-risk  patients
[7].  Nevertheless,  in  recent  studies  [2,5],  the  percentage  of
patients  who  were  either  dead  or  severely  symptomatic  at
6  months  was  about  25%,  highlighting  that  it  is  still  unclear
which  patients  are  most  likely  to  beneﬁt  from  this  proce-
dure.
Indeed,  although  numerous  studies  have  identiﬁed  pre-
dictors  of  mortality  [2,3,6,8,9],  few  of  them  have  focused  on
predictors  of  functional  results  [8,16,17].  Thus,  a  strength
of  the  present  study  was  the  identiﬁcation  of  predictors
of  ‘global’  clinical  6-month  poor  outcomes  after  TAVI  with
both  valves,  in  routine  clinical  practice  and  using  all  possi-
ble  accesses.  One  of  our  main  ﬁndings  was  the  signiﬁcant
a
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aroportion  of  patients  with  ‘poor  outcomes’.  Moreover,  this
s,  to  the  best  of  our  knowledge,  the  ﬁrst  study  to  high-
ight  the  potential  independent  effect  of  baseline  AR  on  TAVI
utcomes.
trial ﬁbrillation
F  after  TAVI  has  been  associated  with  increased  all-cause
ortality  [18].  In  the  study  by  Stortecky  et  al.,  this  was
ainly  attributable  to  cardiac  mortality,  without  differ-
nces  in  rates  of  systemic  embolic  events  or  fatal  bleedings
etween  patients  with  and  without  AF,  and  irrespective  of
he  type  of  AF.
In  our  study,  AF  was  an  independent  risk  factor  of  6-month
oor  outcomes  because  of  increased  rates  of  heart  fail-
re  events  and  symptom  sustainability.  Given  the  preserved
VEF  presented  by  our  patients,  it  can  be  hypothesized  that
hey  were  more  likely  to  have  heart  failure  with  preserved
jection  fraction.  Indeed,  AS,  by  increasing  the  pressure
fterload  and  wall  stress,  ﬁrst  leads  to  LV  hypertrophy  and
hen  to  myocardial  apoptosis  and  ﬁbrosis,  which  are  key
actors  in  the  progression  towards  heart  failure  [19].  AF,
lso  related  to  myocardial  ﬁbrosis,  might  be  a  marker  of
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Table  2  Procedural  characteristics  and  postprocedural  outcomes.
Variables  All  patients  Good  outcomes  Poor  outcomes  P
(n  =  163)  (n  =  114)  (n  =  49)
Valve  type  0.03
Edwards  (SAPIEN  and  SAPIEN  XT)  99  (60.7)  76  (66.7)  23  (46.9)
Medtronic  CoreValve  64  (39.2)  38  (33.3)  26  (53.1)
Valve  diameter  0.14
23  mm 32  (19.6) 23  (20.2)  9  (18.4)
26  mm 83  (50.9) 62  (54.4) 21  (42.9)
29  mm 40  (24.5) 26  (22.8) 14  (28.6)
31  mm 8 (4.9) 3  (2.6) 5  (10.2)
Vascular  access  0.88
Transfemoral  132  (80.9)  92  (80.7)  40  (81.6)
Subclavian  10  (6.1)  6  (5.3)  4  (8.2)
Transapical  12  (7.4)  9  (7.9)  3  (6.1)
Transaortic 9  (5.5) 7  (6.1) 2  (4.1)
Procedural  time  (minutes) 96  ±  31 97  ±  34 95 ±  24 0.90
Total  amount  of  contrast  agent  (mL)  238.8  ±  92.7  233.2  ±  85.1  252.8  ±  109.0  0.25
Need  for  second  valve  2  (1.2)  1  (0.9)  1  (2.0)  0.51
Hospital  stay  (days)  9.2  ±  5.5  8.4  ±  4.6  11.0  ±  6.8  0.001
ICU  stay  (days)  3.5  ±  2.1  3.2  ±  1.9  4.2  ±  2.6  0.03
Bleeding
Life-threatening  or  disabling  4  (2.5)  2  (1.8)  2  (4.1)  0.58
Major  34  (20.9)  24  (21.1)  10  (20.4)  1.0
Myocardial  infarction  3  (1.8)  3  (2.6)  0  (0.0)  0.55
Stroke  4  (2.5)  3  (2.6)  1  (2.0)  1.0
Major  vascular  complication  16  (9.8)  10  (8.8)  6  (12.2)  0.57
Acute  kidney  injury,  RIFLE  stage  2  or  3  10  (6.1)  3  (2.6)  7  (14.3)  0.009
Need  for  permanent  pacemaker  implantation  16  (9.8)  6  (5.3)  10  (20.4)  0.007
Postoperative  treatment
Aspirin  143  (87.7)  102  (90.3)  41  (83.7)  0.35
Clopidogrel  93  (57.1)  74  (65.5)  19  (38.8)  0.003
Vitamin  K  antagonists  56  (34.4)  29  (25.7)  27  (55.1)  0.0006
Diuretics  94  (57.7)  61  (53.9)  33  (67.3)  0.16
Beta-blockers  87  (53.4)  60  (53.6)  27  (55.1)  0.99
ACE  inhibitors/ARBs 80  (49.1)  62  (54.9)  18  (36.7)  0.05
Data are mean ± standard deviation or number (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; ICU:
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hintensive care unit.
uch  evolved  AS,  highlighting  the  need  for  rigorous  echocar-
iographical  screening  before  TAVI  and  tailored  medication
pon  discharge  for  these  patients.
ulmonary hypertension
n  TAVI  series,  the  prevalence  of  sPAP  >  60  mmHg  ranged
rom  11%  to  32%  [9,20].  There  is  consistent  evidence  that
ulmonary  hypertension  is  an  independent  predictor  of  mor-
ality  in  AS  patients  [9,21].  Worse  functional  results  after
AVI  have  also  been  highlighted  [22].
Diastolic  dysfunction  and  AF  are  considered  to  be  major
eterminants  of  pulmonary  hypertension  in  patients  with
evere  AS  [21,23].  As  previously  discussed,  these  factors
eﬂect  the  detrimental  haemodynamic  effects  of  evolved
S,  leading  to  a  vicious  circle.  Whether  these  effects  can
e  relieved  by  TAVI  is  a  major  concern.  Indeed,  although
AVI  has  been  shown  to  improve  sPAP  during  the  ﬁrst  year
23],  Roselli  et  al.  [21]  demonstrated  that,  after  this  initial
p
t
p
mmprovement,  there  was  a  progressive  rise  towards  the  pre-
perative  level  of  sPAP  in  about  3.5  years  after  SAVR.  Given
he  large  number  of  TAVI  candidates  with  reactive  pulmonary
ypertension,  almost  50%  of  patients  with  sPAP  >  60  mmHg
23], it  suggests  that  patients  with  longstanding  AS  have  pul-
onary  vasculature  abnormalities  that  maintain  pulmonary
ypertension  and  worsen  outcomes.
ight ventricular dysfunction
t  has  been  shown  that  under  the  inﬂuence  of  various  factors
uch  as  pericardiotomy,  hypothermia,  inﬂammation  and  pro-
onged  cardiopulmonary  bypass,  RV  function  decreases  after
AVR,  which  is  not  observed  after  TAVI  [24]. Some  authors
ave  therefore  recommended  that  RV  dysfunction  should
rompt  TAVI  to  be  favoured  over  SAVR  [24,25].  Nonetheless,
here  are  no  data  supporting  the  fact  that  patients  with
re-existing  RV  dysfunction  experience  functional  improve-
ent  after  TAVI.  We  showed  that  RV  dysfunction  was  an
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Table  3  Echocardiographical  ﬁndings.
Variables  All  patients  Good  outcomes  Poor  outcomes  P
(n  =  163)a (n  =  114)  (n  =  49)b
At  baseline
LVEF  (%)  50.7  ±  14.8  50.2  ±  15.1  51.9  ±  14.0  0.48
LV  end-diastolic  diameter  (mm)  50.1  ±  7.9  50.5  ±  7.9  49.3  ±  7.9  0.32
LV  end-systolic  diameter  (mm)  36.1  ±  9.5  36.4  ±  9.9  35.5  ±  8.6  0.54
End-diastolic  septal  thickness  (mm)  13.3  ±  2.6  13.3  ±  2.8  13.4  ±  2.4  0.96
Aortic  annulus  diameter  (mm) 22.9  ±  2.1  22.7  ±  2.0  23.5  ±  2.1  0.05
Indexed  aortic  valve  area  (cm2/m2) 0.38  ±  0.10 0.38  ±  0.11 0.39  ±  0.09 0.27
Aortic  mean  gradient  (mmHg) 50.8  ±  15.5 53.0  ±  15.9 45.7  ±  13.6 0.006
Moderate  or  severe  AR 36  (22.1) 32  (28.1) 4  (8.2) 0.004
Moderate  or  severe  MR  65  (39.9)  42  (36.8)  23  (46.9)  0.30
Left  atrial  area  (cm2)  28.0  ±  6.6  26.9  ±  6.5  30.5  ±  6.2  0.002
RV  dysfunction  31  (19.0)  15  (15.2)  16  (32.7)  0.007
Moderate  or  severe  TR 38  (23.3) 17  (14.9)  21  (42.9)  0.0002
Pulmonary  hypertension 106  (65.0) 69  (60.5) 37  (75.5)  0.0007
40  mmHg  ≤  sPAP  ≤  50  mmHg 70  (42.9) 53  (46.5) 17  (34.7)  0.173
sPAP  ≥  60  mmHg 36  (22.1) 16  (14.0) 20  (40.8) <  0.001
Postoperative  assessment
Aortic  valve  area  (cm2)  1.87  ±  0.53  1.85  ±  0.53  1.90  ±  0.55  0.48
Aortic  mean  gradient  (mmHg)  10.5  ±  4.2  10.9  ±  3.8  9.7  ±  4.9  0.01
Moderate  or  severe  AR  30  (18.6)  16  (14.2)  14  (29.2)  0.04
Patient-prosthesis  mismatch  0.33
Moderate  44  (27.0)  29  (26.4)  15  (31.3)
Severe  8  (4.9)  4  (3.6)  4  (8.3)
6-month  follow-up
LVEF  (%)  55.9  ±  9.8  56.0  ±  9.6  55.6  ±  10.6  0.95
Aortic  valve  area  (cm2)  1.82  ±  0.6  1.77  ±  0.45  1.89  ±  0.69  0.81
Moderate  or  severe  AR  29  (19.0)  19  (16.7)  10  (26.3)  0.21
Moderate  or  severe  MR  25  (16.4)  15  (13.2)  10  (26.3)  0.15
Moderate  or  severe  TR  21  (13.8)  7  (6.1)  14  (36.8)  <  0.001
Pulmonary  hypertension  56  (36.8)  32  (28.1)  24  (63.2)  <  0.001
Data are mean ± standard deviation or number (%). AR, aortic regurgitation; LV: left ventricular; LVEF, left ventricular ejection fraction;
MR: mitral regurgitation; RV, right ventricular; sPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation.
a n = 152 at 6-month follow-up.
b n = 49 at 6-month follow-up.
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aindependent  predictor  of  poor  outcomes,  which  is  in  line
with  previous  observations  in  the  setting  of  SAVR  [24].
Recently,  Poliacikova  et  al.  [25]  reported  the  outcomes
of  155  patients.  In  this  study,  RV  dysfunction  was  noted
in  about  10%  of  patients  and  was  not  associated  with  an
unfavourable  prognosis.  Nevertheless,  a  higher  mortality
rate  was  observed  in  patients  with  RV  dysfunction,  and
low  mortality  rates  in  this  study  might  have  prevented  this
trend  from  reaching  statistical  signiﬁcance.  Besides,  in  our
study,  RV  dysfunction  was  an  independent  predictor  of  func-
tional  outcomes,  which  were  not  assessed  in  the  previous
study.  Consequently,  we  believe  that  RV  function  should  be
assessed  carefully  and  taken  into  account  during  patient
selection.Aortic regurgitation
Our  ﬁnding  that  patients  with  baseline  AR  ≥  2/4  had  a
lower  risk  of  poor  outcomes  may  seem  counterintuitive,  as
T
u
v
eR  ≥  2/4  has  been  shown  to  lower  the  event-free  survival  of
atients  with  medically-managed  AS  [26]. However,  there
s  no  evidence  that  patients  with  such  an  AR  have  worse
utcomes  after  SAVR  [27].
AR  is  much  more  frequent  after  TAVI  than  after  SAVR  and
 recent  meta-analysis  showed  a  pooled  estimate  of  12%
or  postprocedural  AR  ≥  2/4  [28,29]. There  is  now  consistent
vidence  that  such  an  AR  impacts  negatively  on  survival  and
unctional  results  after  TAVI  [2,3,6,8,28,29].
A  haemodynamic  study  by  Azadani  et  al.  [30]  showed  sub-
tantial  energy  loss  during  diastole,  even  with  mild  AR,  after
mplantation  of  a  transcatheter  valve  resulting  in  higher
V  workload.  Indeed,  postprocedural  AR  mimics  the  phys-
opathology  of  acute  AR,  subjecting  a  hypertrophied  LV
ccustomed  to  pressure  overload  to  volume  overload  [29].
he  LV  is  unable  to  properly  increase  its  end-diastolic  vol-
me  because  of  impaired  relaxation.  Thus,  the  regurgitation
olume  precipitates  an  elevation  in  the  already  increased
nd-diastolic  pressure,  whereas  forward  stroke  volume
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Table  4  Univariate  and  multivariable  predictors  of  poor  outcomes.
Variables  Univariate  OR  (95%  CI)  P  Multivariable  OR  (95%  CI)  P
Agea 1.09  (1.03—1.16)  0.005  —  —
Logistic  EuroSCOREa 1.03  (0.99—1.06)  0.09  —  —
STS  risk  scorea 1.16  (1.04—1.29)  0.008  —  —
Syncopeb 0.21  (0.05—0.95)  0.04  —  —
CADb 0.59  (0.30—1.15)  0.12  —  —
PVDb 0.47  (0.18—1.23)  0.13  —  —
Prior  valvuloplastyb 2.21  (0.97—5.05)  0.06  —  —
AFb 4.72  (2.29—9.72)  <  0.001  3.94  (1.67—9.29)  0.002
Chest  wall  irradiationb 0.21  (0.05—0.95)  0.04  —  —
Hypertensionb 2.54  (1.16—5.60)  0.02  —  —
Valve  typeb 2.26  (1.14—4.48)  0.02  —  —
Annulus  diametera 1.20  (1.02—1.42)  0.03  —  —
Aortic  mean  gradienta 0.97  (0.95—0.99)  0.007  —  —
Left  atrial  areaa 1.09  (1.03—1.16)  0.003  —  —
AR  ≥  2/4b 0.23  (0.08—0.69)  0.008  0.07  (0.02—0.32)  0.001
TR  ≥  2/4b 4.28  (1.99—9.20)  <  0.001  —  —
RV  dysfunctionb 3.20  (1.43—7.17)  0.005  3.55  (1.21—10.39)  0.02
sPAP  ≥  60  mmHgb 4.22  (1.94—9.19)  <  0.001  7.56  (2.58—22.17)  <  0.001
AF: atrial ﬁbrillation; AR: aortic regurgitation; CAD: coronary artery disease; CI: conﬁdence interval; OR: odds ratio; PVD: peripheral
vascular disease; RV: right ventricular; sPAP: systolic pulmonary artery pressure; STS: Society of Thoracic Surgeons; TR: tricuspid
regurgitation.
a Age: for each increase of 1 year; logistic EuroSCORE and STS risk score: for each increase of 1%; annulus diameter: for each increase
of 1 mm; aortic mean gradient: for each increase of 1 mm Hg; left atrial area: for each increase of 1 cm2.
b Reference values: for syncope, CAD, PVD, prior valvuloplasty, AF, chest wall irradiation, hypertension and RV dysfunction: absence of
TR: T
d
r
w
d
c
bthe variable; for valve type: Edwards valve; for AR: AR < 2/4; for 
ecreases.  Furthermore,  the  increased  LV  ﬁlling  pressure
esults  in  an  additional  reduction  in  coronary  perfusion,
hich  is  already  affected  due  to  pre-existing  myocar-
ial  hypertrophy.  Eventually,  these  dramatic  haemodynamic
hanges  promote  symptom  sustainability.
o
F
e
Table  5  Univariate  and  multivariable  predictors  of  clinical  ef
Variables  Univariate  OR  (95%  CI)  
Agea 1.07  (1.02—1.12)  
Logistic  EuroSCOREa 1.02  (0.99—1.05)  
STS  risk  scorea 1.12  (1.01—1.24)  
Syncopeb 0.38  (0.13—1.10)  
PVDb 0.56  (0.24—1.26)  
Prior  valvuloplastyb 2.23  (0.99—5.06)  
AFb 4.37  (2.25—8.48)  
Chest  wall  irradiationb 0.50  (0.18—1.37)  
Hypertensionb 1.63  (0.83—3.20)  
Annulus  diametera 1.20  (1.03—1.41)  
Aortic  mean  gradienta 0.98  (0.96—0.99)  
Left  atrial  areaa 1.05  (0.99—1.10)  
AR  ≥  2/4b 0.23  (0.08—0.69)  
TR  ≥  2/4b 2.28  (1.09—4.78)  
sPAP  ≥  60  mmHgb 3.12  (1.44—6.73)  
AF: atrial ﬁbrillation; AR: aortic regurgitation; CI: conﬁdence interval
pulmonary artery pressure; STS: Society of Thoracic Surgeons; TR: tric
a Age: for each increase of 1 year; logistic EuroSCORE and STS risk sco
of 1 mm; aortic mean gradient: for each increase of 1 mmHg; left atria
b Reference values: for syncope, PVD, prior valvuloplasty, AF, chest wa
AR < 2/4; for TR: TR < 2/4; for sPAP: sPAP < 60 mmHg.R < 2/4; for sPAP: sPAP < 60 mmHg.
We  assume  that  patients  with  signiﬁcant  baseline  AR  may
e  ‘tolerant’  to  postprocedural  AR.  This  might  be  the  result
f  less-altered  myocardial  compliance  and  LV  remodelling.
uture  studies  should  investigate  the  potential  independent
ffect  of  preoperative  AR  on  TAVI  outcomes.
ﬁcacy.
P  Multivariable  OR  (95%  CI)  P
0.01  —  —
0.11  —  —
0.04  —  —
0.07  —  —
0.16  —  —
0.05  —  —
<  0.001  4.09  (1.99—8.39)  <  0.001
0.18  —  —
0.15  —  —
0.02  —  —
0.04  —  —
0.07  —  —
0.008  0.30  (0.11—0.79)  0.015
0.03  —  —
0.004  3.84  (1.52—9.72)  0.004
; OR: odds ratio; PVD: peripheral vascular disease; sPAP: systolic
uspid regurgitation.
re: for each increase of 1%; annulus diameter: for each increase
l area: for each increase of 1 cm2.
ll irradiation and hypertension: absence of the variable; for AR:
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Table  6  Univariate  and  multivariable  predictors  of  all-cause  mortality.
Variables  Univariate  HR  (95%  CI)  P  Multivariable  HR  (95%  CI)  P
Agea 1.08  (0.97—1.21)  0.16  —  —
STS  risk  scorea 1.28  (1.09—1.50)  0.003  1.32  (1.11—1.57)  0.002
NYHA  functional  class  III  or  IVb 3.91  (0.5—30.51)  0.19  —  —
Prior  valvuloplastyb 4.00  (1.22—13.11)  0.02  4.31  (1.26—14.70)  0.02
AFb 2.39  (0.70—8.16)  0.17  —  —
Valve  typeb 2.85  (0.83—9.72)  0.10  —  —
Annulus  diametera 1.32  (1.02—1.72)  0.04  1.50  (1.12—2.00)  0.007
Left  atrial  areaa 1.13  (1.03—1.24)  0.01  1.12  (1.01—1.25)  0.04
Permeability  indexa 0.82  (0.70—0.96)  0.01  —  —
MR  ≥  2/4b 2.68  (0.78—9.15)  0.12  —  —
sPAP  ≥  60  mmHgb 4.42  (1.35—14.47)  0.01  —  —
AF: atrial ﬁbrillation; CI: conﬁdence interval; OR: odds ratio; MT: mitral regurgitation; NYHA: New York Heart Association; sPAP: systolic
pulmonary artery pressure; STS: Society of Thoracic Surgeons.
a Age: for each increase of 1 year; STS risk score: for each increase of 1%; annulus diameter: for each increase of 1 mm; left atrial area:
for each increase of 1 cm2; permeability index: for each increase of 1%.
b Reference values: for NYHA functional class: NYHA functional class I or II; for prior valvuloplasty and AF: absence of the variable; for
valve type: Edwards valve; for MR: MR < 2/4; for sPAP: sPAP < 60 mmHg.
R
[Limitations
When  interpreting  results  of  this  study,  some  limitations
need  to  be  acknowledged.  First,  we  have  reported  on  the
experience  of  a  single  tertiary-care  referral  centre  with  a
small  population.  Thus,  our  results  are  primarily  hypothesis-
generating  and  ought  to  be  conﬁrmed  in  larger  studies.
Second,  we  had  no  standardized  evaluation  of  frailty,  which
has  recently  been  pointed  out  as  a  predictor  of  functional
decline  and  mortality  after  TAVI  [17].  Lastly,  despite  rigorous
prospective  follow-up,  there  was  no  external  adjudication  of
events.
Conclusion
About  one-third  of  patients  in  the  present  study  had  poor
outcomes  after  TAVI.  AF,  severe  baseline  pulmonary  hyper-
tension  and  RV  dysfunction  (i.e.  variables  suggesting  a  more
evolved  AS)  were  predictors  of  6-month  poor  outcomes.  Con-
versely,  baseline  AR  ≥  2/4  showed  a  protective  effect,  which
needs  to  be  conﬁrmed  in  future  studies.  Our  study  highlights
the  need  for  a  speciﬁc  ‘TAVI  risk  score’,  which  could  lead  to
better  selection  of  patients.
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